It is widely accepted that if one is to follow the ethical tenets of clinical equipoise, phase III controlled clinical trials must be designed pragmatically, to measure effectiveness rather than efficacy. This choice of a pragmatic rather than an explanatory approach to phase III clinical trial design has a number of consequences, some of which may be considered problematic. These include changes in what the trial is expected to accomplish, the way treatments are defined, the selection of subjects, the ways in which treatments are compared, and the assessment of the results. One also may end up challenging the real-world expectation that scientific results will be replicated before they are considered valid. This article discusses the connection between clinical equipoise and pragmatic trials, contrasts explanatory with pragmatic trials, points to the differences in the ways in which trial data are analyzed and interpreted, and discusses the power of replication, one of the defining hallmarks of the scientific method. Viewing clinical equipoise through a consequentialist lens reveals a number of problems, many of which are attributable to equipoise's insistence on a pragmatic approach to trial architecture.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1353/pbm.0.0161 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Reconsideration of Small Sample Studies and Absence of Equipoise as Ethical Issues in Research.
Indian J Psychol Med
January 2025
Dept. of Clinical Psychopharmacology and Neurotoxicology, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka, India.
In studies such as randomized controlled trials (RCTs), ethical requirements, inter alia, are that the study should be powered to detect the smallest clinically significant difference between treatments, and that the treatment groups should be in equipoise at the start of the trial. This article provides examples of circumstances where small sample, potentially underpowered studies may be justifiable, and where RCTs of treatments that are not in equipoise may be considered appropriate. The concepts presented may be extendable from RCTs to other study designs, as well.
View Article and Find Full Text PDFPractice Current-Surveys Navigating Equipoise in Clinical Neurology Worldwide: Stepping Outside of the Echo Chambers.
Neurol Clin Pract
February 2025
Department of Neurology, Children's National Hospital, Washington, DC.
Trochleoplasty Utilization in the Management of Patellofemoral Instability: Results From an International Survey of Surgeons.
Orthop J Sports Med
January 2025
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Background: Considerable variability exists in the described clinical and radiographic indications for use, surgical techniques, postoperative management, and risk profile after trochleoplasty for the management of patellofemoral instability (PFI). In areas of clinical uncertainty, a cohesive summary of expert opinion and identification of areas of variation in current practice can be useful in guiding current practice and future research efforts.
Purpose: To assess the current indications for use, surgical techniques, postoperative rehabilitation practices, and observed complication profile for trochleoplasty in the management of PFI among surgeons who perform this procedure.
The Society of Thoracic Surgeons (STS) Clinical Practice Guideline on Surgical Management of Oligometastatic Non-small Cell Lung Cancer.
Ann Thorac Surg
January 2025
Thoracic Surgery Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Background: The use of local consolidative therapy (LCT) in patients with oligometastatic non-small cell lung cancer (NSCLC) is rapidly evolving, with a preponderance of data supporting the benefits of such therapeutic approaches incorporating pulmonary resection for appropriately selected candidates. However, practices vary widely institutionally and regionally, and evidence-based guidelines are lacking.
Methods: The Society of Thoracic Surgeons assembled a panel of thoracic surgical oncologists to evaluate and synthesize the available evidence regarding the role of pulmonary resection as LCT.
Percutaneous coronary intervention for stable late ST-elevation myocardial infarction with symptoms onset between 12 and 72 h - A systematic review.
Cardiovasc Revasc Med
December 2024
Heart and Vascular Institute, University of Pittsburgh Medical Center, United States.
Background: There exists clinical equipoise regarding whether and when an invasive approach should be preferred over conservative treatment in the management of stable late ST-elevation myocardial infarction (STEMI) presenting within 12 to 72 h of symptom onset.
Objective: To perform a systematic review to identify the most effective treatment strategy between percutaneous coronary intervention (PCI) and medical therapy in stable late STEMI presenters by comparing their respective outcomes as well as determine the optimal timing of PCI by evaluating the outcomes of urgent versus non-urgent PCI approach in this patient population.
Methods: PubMed, Embase, and Cochrane databases were queried from inception until March 2024 for studies comparing the outcomes of PCI versus medical therapy, as well as urgent versus non-urgent PCI, in stable late STEMI patients presenting with symptom onset within 12-72 h.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!